Fulcrum Therapeutics (FULC) is planning to raise $76 million in an initial public offering (IPO) on Thursday, July 18th, IPO Scoop reports. The company will issue 4,500,000 shares at $16.00-$18.00 per share.
Fulcrum Therapeutics has a market-cap of $396.8 million.
Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.
Fulcrum Therapeutics provided the following description of their company for its IPO: ” We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. We have developed a proprietary product engine that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. We are using our product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression. “.
Fulcrum Therapeutics was founded in 2015 and has 62 employees. The company is located at 26 Landsdowne Street, Cambridge, MA 02139, US and can be reached via phone at (617) 651-8851 or on the web at http://www.fulcrumtx.com.
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.